Advertisement

Journal of Neuro-Oncology

, Volume 141, Issue 1, pp 213–221 | Cite as

Management and survival trends for adult patients with malignant gliomas in the setting of multiple primary tumors: a population based analysis

  • Ha Son NguyenEmail author
  • Ninh B. Doan
  • Michael Gelsomino
  • Saman Shabani
  • Ahmed J. Awad
  • Mayank Kaushal
  • Martin M. Mortazavi
Clinical Study

Abstract

Introduction

The impact of multiple primary tumors, in the setting of malignant glioma (MG), has not been heavily explored.

Methods

We extracted demographics and clinical data from the SEER-18 registry for adult patients with MGs. The cases were separated based on the sequence of MG diagnosis relative to the other primary tumors: Group (A) One primary only or first primary of multiple primaries and Group (B) second primary or subsequent primary tumor. Incidences, frequencies, and glioma-related survivals were analyzed.

Results

Group B constituted 12.8% of new MG. The incidences of group B, relative to those of all new MG, range from 0.14 to 0.18. Compared to group A, group B exhibited an older age. Moreover, group B exhibited a higher proportion of females, Caucasians, smaller tumors, non-operative cases, and those receiving radiation (p < 0.05); the proportion with GTR remained comparable. Multiple groupings (oral cavity, digestive system, respiratory system, skin, breast, genital systems, urinary system, lymphoma) exhibited lower glioma-related observed survival (p < 0.05) compared to Group A. An active diagnosis of “leukemia” appears to confer longer glioma-related survival while a history of “breast” or “digestive system” malignancies portends a shorter glioma-related survival.

Conclusion

For newly diagnosed MG, a high proportion does have history of extra-CNS primary tumors. Generally, these patients appear to have worse glioma-related observed survival compare to those with malignant glioma as the only primary or the first of multiple primary tumors. Knowledge regarding epidemiology, clinical factors, and observed survival can help guide clinical management/consultation for this subset of patients.

Keywords

Multiple primary tumors Glioblastoma Gliosarcoma Malignant glioma Epidemiology SEER 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Leading Causes of Death (2018) In: National Center for Health Statistics, vol 2018Google Scholar
  2. 2.
    Cancer Statistics (2018) In: National Cancer Institute, vol 2018Google Scholar
  3. 3.
    Frodin JE, Ericsson J, Barlow L (1997) Multiple primary malignant tumors in a national cancer registry–reliability of reporting. Acta Oncol 36:465–469CrossRefGoogle Scholar
  4. 4.
    Moertel CG (1964) Incidence and significance of multiple primary malignant neoplasms. Ann NY Acad Sci 114:886–895CrossRefGoogle Scholar
  5. 5.
    Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK (2016) Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 126:527–533CrossRefGoogle Scholar
  6. 6.
    Boukerroucha M, Josse C, Segers K, El-Guendi S, Freres P, Jerusalem G et al (2015) BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer 15:181CrossRefGoogle Scholar
  7. 7.
    Freedman RA, Wirth LJ, Chirieac LR, Huang EC (2007) Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol 25:2848–2850CrossRefGoogle Scholar
  8. 8.
    Hayashi K, Ohtsuki Y, Sonobe H, Takahashi K, Wada S, Yoshida K (1987) An autopsy case of triple primary cancers consisting of glioblastoma multiforme of the pons, colon cancer and rectal carcinoid—a statistical analysis of cases of brain tumor combined with other primary cancers in Japan autopsy annuals. Gan No Rinsho 33:1846–1853Google Scholar
  9. 9.
    Raufi A, Alsharedi M, Khelfa Y, Tirona M (2017) Bilateral triple-negative invasive breast cancer with a BRCA2 mutation, and glioblastoma: a case report and literature review. J Breast Cancer 20:108–111CrossRefGoogle Scholar
  10. 10.
    Epidemiology S, Results E (SEER) Program: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases. In: National Cancer Institute Division. Surveillance Research Program, Surveillance Systems BranchGoogle Scholar
  11. 11.
    Lin Y, Jea A, Melkonian SC, Lam S (2015) Treatment of pediatric Grade II spinal ependymomas: a population-based study. J Neurosurg Pediatr 15:243–249CrossRefGoogle Scholar
  12. 12.
    Nguyen HS, Doan N, Gelsomino M, Shabani S (2017) Dysembryoplastic neuroectodermal tumor: an analysis from the surveillance, epidemiology, and end results program, 2004–2013. World Neurosurg 103:380–385CrossRefGoogle Scholar
  13. 13.
    Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850CrossRefGoogle Scholar
  14. 14.
    Nguyen HS, Shabani S, Awad AJ, Kaushal M, Doan N (2018) Molecular markers of therapy-resistant glioblastoma and potential strategy to combat resistance. Int J Mol Sci 19:1765CrossRefGoogle Scholar
  15. 15.
    Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS et al (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev 23:1985–1996CrossRefGoogle Scholar
  16. 16.
    Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH et al (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 121:1115–1123CrossRefGoogle Scholar
  17. 17.
    Baker P (2016) Men’s health: an overlooked inequality. Br J Nurs 25:1054–1057CrossRefGoogle Scholar
  18. 18.
    Bates JE, Choi G, Milano MT (2016) Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. J Neurooncol 129:251–258CrossRefGoogle Scholar
  19. 19.
    Kutsenko A, Berrington de Gonzalez A, Curtis RE, Rajaraman P (2014) Risk of second benign brain tumors among cancer survivors in the surveillance, epidemiology, and end results program. Cancer Causes Control 25:659–668CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurosurgeryMedical College of WisconsinMilwaukeeUSA
  2. 2.National Skull Base CenterThousand OaksUSA
  3. 3.California Institute of NeuroscienceThousand OaksUSA
  4. 4.Faculty of Medicine and Health SciencesAn-Najah National UniversityNablusPalestine
  5. 5.Department of NeurosurgeryUniversity of South AlabamaMobileUSA

Personalised recommendations